Major Scope

  •  Colon and Rectal Surgery
  •  General Surgery
  •  Gynecologic Oncology
  •  Plastic Surgery
  •  Neurological Surgery
  •  Orthopaedic Surgery
  •  Orthopaedic Surgery of the Spine
  •  Neonatal Surgery
  •  Prenatal Surgery
  •  Trauma Surgery
  •  Surgical Intensivists, Specializing In Critical Care Patients
  •  Thoracic Surgery
  •  Congenital Cardiac Surgery
  •  Thoracic Surgery-Integrated
  •  Vascular Surgery

Abstract

Citation: Clin Surg. 2019;4(1):2438.Research Article | Open Access

Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis

Jian-Cong Chen, Jun-Cheng Wang, Yao-Jun Zhang, Li Xu, Jin-Bin Chen, Yang-Xun Pan, Ying-Qin Zhu, Min-Shan Chen and Zhong-Guo Zhou

Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, China
Both authors contributed equally to this work

*Correspondance to: Zhong-Guo Zhou 

 PDF  Full Text DOI: 10.25107/2474-1647.2438

Abstract

Background: Pain is one of the most dominating adverse effects in radiofrequency ablation therapy. The purpose of this study is to evaluate the role of parecoxib sodium on pain management in patients with liver cancer undergoing radiofrequency ablation.
Methods: A total of 186 patients diagnosed as liver cancer (including primary cancer 122 cases and metastasis lesion 64 cases) and treated with radiofrequency ablation at Sun Yat-sen University Cancer Center between April 2015 and January 2016 were retrospectively reviewed. About 111 patients achieved the inclusion criteria and were divided into the parecoxib group (experimental group; n=56) and the non-parecoxib group (control group, receiving 0.9% sodium chloride; n=55), according to whether or not the medication was applied. Post-operative pain, vomiting, body temperature, changes in hepatic function, and duration of postoperative hospitalization time were compared between the two groups.
Results: After the propensity score matching analysis, the parecoxib group had suffered less severe pain on postoperative day 0, day 1 and day 2 (with P<0.000, 0.001 and 0.0041, respectively), compared with the non-parecoxib one, along with a lower ALT and CRP levels (177.0 ± 88.0 vs. 327.7 ± 387.1 U/L, P<0.016, and 20.0 ± 29.0 vs. 49.7 ± 44.1 mg/L, P<0.001, respectively), and an insignificant shorter postoperative hospitalization time was witnessed, though not significantly (2.4 ± 0.7 vs. 2.6 ± 0.6 days, P=0.186).
Conclusion: This research illustrated that the preemptive application of parecoxib can remarkably relieve postoperative discomfort, especially controlling post-operative pain, reducing hepatic inflammation, and shortening post-operative hospital stay after radiofrequency ablation for liver cancer.

Keywords

Parecoxib; Postoperative complication control; Pain management; Radiofrequency ablation

Cite the article

Chen J-C, Wang J-C, Zhang Y-J, Xu L, Chen J-B, Pan Y-X, et al. Parecoxib Prevents Postoperative Pain after Radiofrequency Ablation for Liver Cancer: A Propensity Score Matching Analysis. Clin Surg. 2019; 4: 2438.

Journal Basic Info

  • Impact Factor: 2.395**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
  • NLM ID: 101702548

Search Our Journal

Journal Indexed In

Articles in PubMed

Risk Factors for Visual Impairment in an Uninsured Population and the Impact of the Affordable Care Act
 PubMed  PMC  PDF  Full Text
Voice Outcomes in Laryngotracheal Stenosis: Impact of the Montgomery T-tube
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Blockage of Schlemm’s Canal Orifice after Ab-Interno Canaloplasty Surgery for Glaucoma
 Abstract  PDF  Full Text
Continuous Venous Infusion of Adenosine in Patients Undergoing Partial Liver-Resection - a Potential Method to Reduce Ischemia-Reperfusion Damage?
 Abstract  PDF  Full Text
View More...